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Abstract
Backgrounds: Several studies have evaluated the impact of matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) combined with antimicrobial stewardship in patients with positive blood cultures;
clinical outcomes improved. However, in many hospitals, antimicrobial stewardship is not available because of restricted
medical resources. Thus, we investigated the impact of evaluation by MALDI-TOF MS on the clinical outcomes of patients
with bacteremia and fungemia treated in a clinical setting lacking an antimicrobial stewardship program (ASP).
Methods: We designed a pre–post quasi experimental study and retrospectively reviewed the medical records of
patients aged > 18 years old with bacteremia and fungemia during two periods: October–December 2012 and
October–December 2013. Conventional methods were used to detect microbial pathogens in 2012, and MALDI-TOF
MS was employed in 2013. Clinical outcomes compared between periods were the time to pathogen identification,
time to effective therapy, 30-day all-cause mortality, time to microbiological clearance, length of ICU stay, and rate of
recurrence of the same bloodstream infection (BSI).
Results: A total of 556 patients were enrolled; 302 patients in 2012, and 254 in 2013. The use of MALDI-TOF MS
without an ASP reduced the time to pathogen identification (86.4 vs. 63.5 h, P < 0.001) but did not significantly reduce
the time to effective therapy (27.4 vs. 23.2 h, P = 0.187). Also, none of the following differed significantly between the
two periods: mortality (17.5 vs. 15.7%, P = 0.571), the time to microbiological clearance (3.6 vs. 3.7 days, P = 0.675), the
length of ICU stay (16.8 vs. 14.7 days, P = 0.706), and the recurrence rate of the same BSI (5.0 vs. 2.8%, P = 0.183).
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Conclusions: The use of MALDI-TOF MS alone in a setting lacking an ASP did not afford clinical benefits. An ASP
combined with MALDI-TOF MS is necessary to improve clinical outcomes.
Keywords: Matrix-assisted laser desorption/ionization time-of-flight, Antimicrobial stewardship program, Bacteremia,
Fungemia, Clinical outcome
Background
Despite considerable advances in medical technology
and antibiotics, bloodstream infections (BSIs) are still
associated with high-level mortality and morbidity [1].
The early administration of effective antibiotics is associ-
ated with improved clinical outcomes in patients with
severe sepsis [2–5]. Similarly, early pathogen detection
combined with appropriate therapeutic intervention im-
proves the time to effective antimicrobial therapy and good
clinical outcomes [6].
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) identifies mi-
croorganisms rapidly and accurately [7]. In clinical settings,
MALDI-TOF MS reduces the time to identification by more
than 24 h compared to conventional methods [8, 9].
Along with improvements in medical technology, anti-
microbial stewardship programs (ASPs) have been intro-
duced to care for septic patients and to optimize the use
of antimicrobial agents [10]. However, in many hospitals
around the world, ASPs are not in place because of re-
stricted medical resources [11].
Several studies have shown that MALDI-TOF MS com-
bined with an ASP improved clinical outcomes in patients
with positive blood cultures [12–18]. Huang et al. [13] re-
ported that the use of MALDI-TOF MS combined with
an ASP in patients with bacteremia and candidemia was
associated with improved clinical outcomes, including
the time to effective therapy (30.1 vs. 20.4 h, P = 0.021),
30-day all-cause mortality (20.3% vs. 12.7%, P = 0.021),
and length of intensive care unit (ICU) stay (14.9 vs.
8.3 days, P = 0.014) in univariate analyses, and that ASP
introduction was related to a nonsignificant trend to-
ward reduced mortality (odds ratio, 0.55; P = 0.075) in
multivariate analysis.
However, the clinical responses afforded by MALDI-TOF
MS-based evaluations alone have not been investigated.
Thus, we explored the impact of MALDI-TOF MS on
clinical outcomes (time to pathogen identification, time
to effective therapy, 30-day all-cause mortality, time to
microbiological clearance, length of ICU stay, and rate of
recurrence of the same BSI) in patients with bacteremia
and fungemia treated in a setting lacking an ASP. Because
previous studies that evaluated the clinical impacts of
other rapid diagnostic tests in the absence of an ASP failed
to document the desired clinical outcomes [19, 20], we
hypothesized that the introduction of MALDI-TOF MS
alone would not improve clinical outcomes.
Methods
Study population and design
This retrospective, single-center, pre-post quasi-experimental
study was conducted at Severance Hospital, a 2000-bed
tertiary care hospital in Seoul, Korea. The electronic
medical records of patients aged > 18 years old with
positive blood cultures during two periods (October–
December 2012 and October–December 2013) were
reviewed. The conventional method (employing the ATB
32 GN system) was used to identify microorganisms in
2012, and MALDI-TOF MS was used in 2013. No ASP
was in place during either period. Patients admitted to the
institution for < 2 days after blood culture were excluded.
The clinical outcomes were compared between the two
periods. Our Institutional Review Board and local Ethics
Committee approved the study.
Definitions
Community-acquired BSI was defined as a BSI that devel-
oped within 48 h of hospitalization, and a hospital-acquired
BSI was defined as a BSI developing ≥48 h after
hospitalization [21]. A polymicrobial BSI was defined as
a BSI associated with more than one microorganism.
Patients with cultures positive for coagulase-negative
Staphylococcus and normal skin flora were screened as
contaminants [13]. Contamination was considered present
if coagulase-negative Staphylococcus was detected in only
one of multiple blood cultures from the same patient, ex-
cept when patients were suspected to have been infected
via central venous catheters or foreign devices. We ex-
cluded patients with positive blood cultures, defined as
contaminants.
The clinical outcomes compared were the time to
pathogen identification, time to effective therapy, 30-day
all-cause mortality, time to microbiological clearance,
length of ICU stay, and 30-day rate of recurrence of the
same BSI. The time to effective therapy was defined as
the time from blood collection for culture to the time of
administration of the first antimicrobial agent to which
the pathogen was susceptible in vitro [13]. The time to
microbiological clearance was defined as the time from
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the first positive blood culture to the first negative blood
culture.
Species identification and antimicrobial susceptibility
testing
The microorganisms were identified using the ATB 32
GN system (bioMérieux, Marcy l’Etoile, France) in con-
ventional period. In MALDI-TOF period, blood culture
bottles were subcultured to the appropriate media and
incubated aerobically and anaerobically for 18 to 24 h.
Bacteria were applied as a thin film onto the plate and
allowed to dry at room temperature. Subsequently, 2 μl
of MALDI matrix was applied onto the colony and
allowed to dry before testing. Analysis was done using
MALDI Biotyper (Bruker Daltonics, Bremen, Germany).
According to the criteria proposed by the manufacturer,
an identification was considered reliable at the species
level when the score was x ≥ 2 and at the genus level
when the score was 1.7 ≤ x < 2 [21]. Antimicrobial suscepti-
bility tests were performed using the disk-diffusion method
or a VITEK-2 N131 card (bioMerieux, Hazelwood, MO,
USA). The results were interpreted based on the Clinical
and Laboratory Standards Institute (CLSI) guidelines.
Statistical analysis
A statistical analysis was performed using SPSS for
Windows (ver. 20.0; SPSS Inc., Chicago, IL, USA). Pa-
tient baseline characteristics, microorganism distributions,
and clinical outcomes were compared between the conven-
tional evaluation and MALDI-TOF periods. Continuous
variables were compared using Student’s t-test; categorical
variables were compared with the aid of the chi-squared or
Fisher’s exact test. A two-sided P-value < 0.05 was consid-
ered to reflect statistical significance.
A subgroup analysis of infectious disease (ID) interven-
tion was performed to evaluate the impact of MALDI-TOF
MS combined with such intervention. ID intervention was
defined as admission to the ID division, or ID consultation,
within 3 days after blood cultures were drawn. The clinical
outcomes of the two evaluation periods were compared
between the ID intervention subgroups.
Results
In total, 837 patients with positive blood cultures were
identified during both study periods, and 556 were in-
cluded in the final analysis (Fig. 1). The conventional
period and MALDI-TOF MS period included 302 and
254 patients, respectively.
The baseline characteristics were similar between the
two periods, except for the male: female ratio (Table 1).
The patients in the MALDI-TOF group tended to be
female (53.5 vs. 37.7% in the conventional period, P <
0.001), but no other demographic factor, including age,
underlying disease, clinical condition, BSI acquisition
(community- or hospital-acquired), or BSI source, differed
significantly between the two periods. Sepsis-related organ
failure assessment scores were calculated for all patients
and did not differ significantly between the two periods
(3.7 vs. 4.2, P = 0.110).
The microorganism distributions were also generally
similar between the two periods (Table 2). The polymi-
crobial BSI frequencies were 11.9% in the conventional
period and 10.2% in the MALDI-TOF MS period (P =
0.530). The prevalence of Gram-positive bacteria (33.1
vs. 32.3%, P = 0.821), Gram-negative bacteria (61.5 vs.
60.4%, P = 0.762), and yeasts (5.3 vs. 7.4%, P = 0.294), did
not differ significantly between the two periods.
Compared to the conventional approach, MALDI-TOF
MS performed in the absence of an ASP reduced the time
to pathogen identification (86.4 vs. 63.5 h, P < 0.001) but
did not significantly reduce the time to effective therapy
(27.4 vs. 23.2 h, P = 0.187; Table 3), 30-day all-cause mortal-
ity (17.5% vs. 15.7%, P = 0.571), time to microbiological
clearance (3.6 vs. 3.7 days, P = 0.675), length of ICU stay
(16.8 vs. 14.7 days, P = 0.706), or 30-day rate of recurrence
Fig. 1 Flowchart of selected patients. *Abbreviations; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; ID, infectious disease
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of the same BSI (5.0% vs. 2.8%, P = 0.183). The clinical out-
comes did not differ significantly between the two periods.
Of the 556 study patients, 89 were hospitalized in the
ID division and 65 were referred for ID consultation
within 3 days after blood cultures were drawn. A total of
154 patients were thus included in the ID intervention
subgroup; 79 and 75 in the conventional and MALDI-
TOF MS periods, respectively. Subgroup analysis revealed
that MALDI-TOF MS combined with the ID intervention
significantly improved not only the time to pathogen iden-
tification (86.9 vs. 62.5 h, P < 0.001) but also the time to
effective therapy (27.8 vs. 17.1 h, P = 0.031), compared to
the conventional approach (Table 4). No other outcome,
Table 1 Patient baseline characteristics
Baseline Characteristics Conventional
period
n = 302 (%)
MALDI-TOF
period
n = 254 (%)
P Value†
Age (years), mean ± SD 63.5 ± 12.3 61.6 ± 13.9 0.088
Female 114 (37.7) 136 (53.5) < 0.001
Underlying disease
Solid tumor 169 (56.0) 133 (52.4) 0.396
Hematologic malignancy 27 (8.9) 20 (7.9) 0.653
Cardiovascular disease 54 (17.9) 54 (21.3) 0.316
Cerebrovascular disease 30 (9.9) 35 (13.8) 0.160
Chronic lung disease 7 (2.3) 9 (3.5) 0.389
Chronic liver disease 44 (14.6) 26 (10.2) 0.125
Chronic kidney disease 42 (13.9) 34 (13.4) 0.858
Transplantation 16 (5.3) 11 (4.3) 0.597
Charlson score, median (IQR) 6 (2–7) 6 (2–7) 0.505
Clinical conditions
Prior Chemotherapy within
30 days
81 (26.8) 63 (24.8) 0.588
Neutropenia (ANC < 500
cells/μL)
26 (8.6) 19 (7.5) 0.627
ICU stay 51 (16.9) 47 (18.5) 0.618
SOFA score, mean ± SD 3.7 ± 3.6 4.2 ± 3.6 0.110
Acquisition of BSI
Community acquired 190 (62.9) 165 (65.0) 0.617
Hospital acquired 112 (37.1) 89 (35.0) 0.617
Source of BSI
Urinary tract 61 (20.2) 57 (22.4) 0.519
Respiratory tract 38 (12.6) 23 (9.1) 0.185
Biliary tract 73 (24.2) 63 (24.8) 0.863
Abdomen except biliary tract 29 (9.6) 23 (9.1) 0.825
Central venous catheter 32 (10.6) 27 (10.6) 0.990
Foreign device 5 (1.7) 2 (0.8) 0.462
SSTI/BJI 20 (6.6) 10 (3.9) 0.163
Infective endocarditis 6 (2.0) 4 (1.6) 0.761
Primary Unknown 38 (12.6) 45 (17.7) 0.091
*Abbreviations: MALDI-TOF matrix-assisted laser desorption/ionization time-of-
flight, IQR interquartile range, ANC absolute neutrophil count, ICU intensive
care unit, SOFA score sepsis related organ failure assessment score, BSI
bloodstream infection, SSTI skin and soft tissue infection, BJI bone and
joint infection
†P-values were calculated using the chi-square or Fisher’s exact test for
categorical variables and Student’s t-test for continuous variables
Table 2 Microorganism distribution
Microorganism Conventional
period
Number (%)
MALDI-TOF
period
Number (%)
P Value†
Polymicrobial BSI 36/302 (11.9) 26/254 (10.2) 0.530
Total number of organisms 338 285
Gram-positive bacteria 112 (33.1) 92 (32.3) 0.821
Staphylococcus aureus 29 (8.6) 20 (7.0) 0.470
MRSA 16 (4.7) 12 (4.2) 0.754
Coagulase-negative
staphylococcus
26 (7.7) 14 (4.9) 0.158
Streptococcus spp 16 (4.7) 23 (8.1) 0.087
Enterococcus spp 32 (9.5) 24 (8.4) 0.649
Other gram-positive bacteria 9 (2.7) 11 (3.9) 0.398
Gram-negative bacteria 208 (61.5) 172 (60.4) 0.762
Escherichia coli 94 (27.8) 81 (28.4) 0.866
Klebsiella spp 45 (13.3) 40 (14.0) 0.794
Acinetobacter spp 16 (4.7) 9 (3.2) 0.318
Enterobacter spp 12 (3.6) 5 (1.8) 0.170
Pseudomonas aeruginosa 6 (1.8) 6 (2.1) 0.765
Citrobacter spp 3 (0.9) 8 (2.8) 0.070
Serratia spp 3 (0.9) 3 (1.1) > 0.999
Proteus spp 4 (1.2) 4 (1.4) > 0.999
Other gram-negative bacteria 25 (7.4) 16 (5.6) 0.371
Yeast 18 (5.3) 21 (7.4) 0.294
Candida spp 17 (5.0) 21 (7.4) 0.224
Cryptococcus spp 1 (0.3) 0 (0.0) > 0.999
*Abbreviations: MALDI-TOF matrix-assisted laser desorption/ionization time-of-
flight, BSI bloodstream infection, MRSA methicillin resistant Staphylococcus aureus
†P-values were calculated using the chi-square or Fisher’s exact test
Table 3 Clinical outcomes
Outcomes Conventional
period
n = 302 (%)
MALDI-TOF
period
n = 254 (%)
P Value†
Time to pathogen
identification (hours)
86.4 ± 30.0 63.5 ± 23.3 < 0.001
Time to effective therapy (hours) 27.4 ± 35.8 23.2 ± 34.2 0.187
30-day all-cause mortality 53 (17.5) 40 (15.7) 0.571
Time to microbiological
clearance (days)
3.6 ± 2.4 3.7 ± 2.8 0.675
Length of ICU stay (days) 16.8 ± 31.7 14.7 ± 22.0 0.706
30-day Recurrence of same BSI 15 (5.0) 7 (2.8) 0.183
*Abbreviations: MALDI-TOF matrix-assisted laser desorption/ionization time-of-
flight, ICU intensive care unit, BSI bloodstream infection
†P-values were calculated using the chi-square or Fisher’s exact test for
categorical variables and Student’s t-test for continuous variables
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including 30-day all-cause mortality (8.9 vs. 6.7%, P =
0.612), the time to microbiological clearance (4.1 vs.
3.4 days, P = 0.081), the length of ICU stay (14.1 vs.
11.7 days, P = 0.719), and the 30-day recurrence rate
of the same BSI (2.0 vs. 0.0%, P = 0.183), differed sig-
nificantly during either period in the ID intervention
subgroup.
Discussion
Most studies of the effects of MALDI-TOF mass spec-
trometric evaluation have been conducted in clinical set-
tings featuring ASPs [12–18]. Of the hospitals included
in one international survey, 58% had ASPs, but the rates
were low in Africa (14%), South and Central America
(46%), and Oceania (47%) [11]. Many hospitals do not
adopt ASPs because of a lack of funds, personnel, and/or
information technology, or prescriber opposition. How-
ever, few studies have explored the clinical outcomes
afforded by MALDI-TOF MS in clinical settings lacking
ASPs. In an observational study, Clerc et al. [21] explored
the utility of the MALDI-TOF MS-based identification of
Gram-negative pathogens in patients with BSIs who were
not enrolled in an ASP, but included only patients who
underwent ID consultations. We studied bacteremic and
fungemic patients regardless of ID consultation status; this
may reflect the real clinical situation in hospitals lacking
ASPs.
We found that evaluation by MALDI-TOF MS in a
setting lacking an ASP did not improve clinical out-
comes. MALDI-TOF MS reduced the time to pathogen
identification (86.4 vs. 63.5 h, P < 0.001), but the time to
effective therapy did not significantly differ from that
achieved with the conventional approach (23.2 vs. 27.4 h).
Other outcomes, including 30-day all-cause mortality, the
time to microbiological clearance, the length of ICU stay,
and the 30-day recurrence rate of the same BSI, did not
differ significantly between the two periods. Another
study showed that MALDI-TOF MS used with an ASP
reduced the time to pathogen identification (84 vs. 55.9 h,
P = 0.001), leading to improved clinical outcomes [13].
These findings are consistent with those of previous studies
evaluating the clinical impacts of other rapid diagnostic
tests in the absence of ASPs [19, 20]. Trep et al. [19] evalu-
ated the impact of rapid methicillin-resistant Staphylococ-
cus aureus polymerase chain reaction testing in patients
with purulent skin infections. Clinical outcomes did not
improve; the introduction of a rapid diagnostic test in the
absence of an effective implementation strategy failed to
produce the desired results. Another study investigated
the impact of peptide nucleic acid fluorescence in situ
hybridization evaluation in patients with coagulase-negative
Staphylococcus bacteremia [20]. Again, no clinical benefit in
terms of the length of hospital stay or vancomycin use was
apparent in the absence of an ASP.
The use of MALDI-TOF MS significantly reduced the
time to effective therapy in the ID intervention sub-
group; the time was 27.8 h in the conventional period,
and 17.1 h in the MALDI-TOF MS period (P = 0.031).
This finding suggests that the ID intervention helped to
reduce the time to effective therapy, in line with the
findings of other reports showing that MALDI-TOF MS
combined with antimicrobial stewardship improves clin-
ical outcomes [12–18]. Our findings thus support the im-
portance of the role of the ID specialist and an ASP.
Huang et al. [13] reported that MALDI-TOF with ASP
in patients with bacteremia and candidemia reduced not
only time to effective therapy (30.1 vs 20.4 h, P = 0.021)
but also 30-day all-cause mortality (20.3% vs 12.7%, P =
0.021) and length of ICU stay (14.9 vs 8.3 days, P =
0.014) in univariate analysis. In the present study, ID
subgroup analysis revealed no significant reductions in
30-day all-cause mortality (8.9% vs. 6.7%, P = 0.612) or
length of ICU stay (14.1 vs. 11.7 days, P = 0.719). However,
the ID intervention of our study was not equivalent to an
ASP. The principal focus of our study was on whether
evaluation by MALDI-TOF MS in a setting lacking an
ASP improved clinical outcomes; we found that it did not.
Our study has several limitations. First, this was a
single-center retrospective cohort study. It may thus be
difficult to generalize our results. Also, any retrospective
study may be subject to selection or information bias.
Second, we did not calculate the appropriate sample size,
which may have contributed to the non-significance of
the difference in time to effective therapy (27.4 vs. 23.2 h,
P = 0.187) in the total group. Third, we censored data
from patients who did not receive effective antibiotics
with in vitro activity, but we used no other technique to
handle censored data. Fourth, follow-up blood culture was
not the same for all patients because this was a retrospect-
ive cohort study. Differences among clinicians in the
Table 4 Clinical outcomes in Infectious disease Intervention
subgroup
Outcomes Conventional
period
n = 79 (%)
MALDI-TOF
period
n = 75 (%)
P Value†
Time to pathogen
identification (hours)
86.9 ± 30.4 62.5 ± 23.1 < 0.001
Time to effective therapy (hours) 27.8 ± 32.4 17.1 ± 25.7 0.031
30-day all-cause mortality 7 (8.9) 5 (6.7) 0.612
Time to microbiological
clearance (days)
4.1 ± 3.0 3.4 ± 2.0 0.081
Length of ICU stay (days) 14.1 ± 26.0 11.7 ± 12.8 0.719
30-day Recurrence of same BSI 2 (2.5) 0 (0.0) 0.497
*Abbreviations: MALDI-TOF matrix-assisted laser desorption/ionization time-of-
flight, ICU intensive care unit, BSI bloodstream infection
†P-values were calculated using the chi-square or Fisher’s exact test for
categorical variables and Student’s t-test for continuous variables
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approach to follow-up blood culture may have resulted in
ascertainment bias.
Conclusions
Our results suggest that the use of MALDI-TOF MS
alone (thus, in a setting lacking an ASP) did not improve
the clinical benefits afforded to patients with bacteremia
and fungemia. Our study strengthens the suggestion that
an ASP is important when seeking to enhance clinical
outcomes.
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